Bevacizumab (BEV),as the first antiangiogenic targeted drug approved by FDA in 2004,has been applied to first-line treatment of metastatic colorectal cancer (mCRC) wildly at present. However,no predictive marker has been identified yet for the efficacy and prognosis of BEV. To solve the clinical problem and determine the individuals who will acquire more benefits from BEV and achieve precise treatment,scholars have carried out many explorations in this field. A literature review was conducted to summarize the research progress and prospect about the predictive factors of BEV in the past years.